2Cagnacci A, Arangino S, Baldassari F, et al. A comparison of the central effects of different progestinsused in hormonereplacement therapy[ J]. Maturitas ,2004,48 (4) : 456-462.
3Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-relesing intrauterine system or hyster- eclomy for treatment of menorrhagia: randomized trial 5-year follow- up[ J]. JAMA ,2004 ,291 (12) : 1456-1463.
4Slap GB. Menstrual disorder in adolescence[ J]. Best Pract Reslin Obster Gynaecol,2003,17( 1 ) : 75-92.
5Barnard ND, Scialli AR, Hurlock D, et al. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms [ J ]. Obstet Gynecol, 2000,95 ( 2 ) :245-250.
6Department of Reproductive Health,WHO.Medical eligibility criteria for contraceptive use[S].2010-08-20.
7Department of Reproductive Health,WHO.Selected practice recommendation for contraceptive use[S].2004-07-05.
8WHO.Decision-making tool for family planning clients and providers[EB/OL].(2007-09-10)[2014-05-30].http://www.who.int/reproductivehealth/publications/family_planning/dmt_cdrom/en/.
9WHO.Family planning:a global handbook for providers[EB/OL].(2011-03-12)[2014-05-15].http://whqlibdoc.who.int/publications/2011/9780978856373_eng.pdf?ua=1.
10Centers for Disease Control and Prevention.U.S.Medical eligibility criteria for contraceptive use,2010:adapted from the World Health Organization medical eligibility criteria for contraceptive use:4th edition[EB/OL].(2010-06-18)[2014-05-16].http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a1.htm.
